| Differences in real-world health and economic outcomes among patients with COPD treated with combination tiotropium/olodaterol versus triple therapy SR Palli, M Frazer, M DuCharme, AR Buikema, AJ Anderson, ... Journal of Managed Care & Specialty Pharmacy 26 (10), 1363-1374, 2020 | 18 | 2020 |
| Costs, exacerbations and pneumonia after initiating combination tiotropium olodaterol versus triple therapy for chronic obstructive pulmonary disease SR Palli, AR Buikema, M DuCharme, M Frazer, S Kaila, T Juday Journal of Comparative Effectiveness Research 8 (15), 1299-1316, 2019 | 12 | 2019 |
| Healthcare resource utilization and costs among patients with steroid-resistant chronic graft-versus-host disease in the United States: a retrospective claims database analysis J Yu, LS Lal, A Anderson, M DuCharme, S Parasuraman, D Weisdorf Current Medical Research and Opinion 37 (5), 755-759, 2021 | 11 | 2021 |
| Healthcare resource utilization and costs associated with acute graft-versus-host disease following allogeneic hematopoietic cell transplantation J Yu, L Lal, A Anderson, M DuCharme, S Parasuraman, D Weisdorf Supportive Care in Cancer 28, 5491-5499, 2020 | 11 | 2020 |
| External validation of a multivariable claims-based rule for predicting in-hospital mortality and 30-day post-pulmonary embolism complications CI Coleman, WF Peacock, GJ Fermann, C Crivera, ER Weeda, M Hull, ... BMC Health Services Research 16, 1-6, 2016 | 7 | 2016 |
| Economic impact of multigene panel testing for hereditary breast and ovarian cancer SD Byfield, H Wei, M DuCharme, JM Lancaster Journal of Comparative Effectiveness Research 10 (3), 207-217, 2020 | 2 | 2020 |
| Healthcare resource utilization (HCRU) and costs among patients with steroid-resistant (SR) chronic graft-vs-host disease (cGVHD) in the United States: a retrospective claims … J Yu, L Lal, A Anderson, M DuCharme, S Parasuraman, DJ Weisdorf Biology of Blood and Marrow Transplantation 25 (3), S244-S245, 2019 | 2 | 2019 |
| Real-world comparison of treatment patterns and effectiveness of albiglutide and liraglutide EK Buysman, MV Sikirica, SW Thayer, M Bogart, MC DuCharme, AV Joshi Journal of Comparative Effectiveness Research 7 (2), 89-100, 2018 | 2 | 2018 |
| Healthcare resource utilization (HCRU) and costs associated with acute graft-vs-host disease (aGVHD) following allogeneic hematopoietic stem cell transplant (a-HSCT): a … J Yu, L Lal, A Anderson, M DuCharme, S Parasuraman, DJ Weisdorf Biology of Blood and Marrow Transplantation 24 (3), S189-S190, 2018 | 1 | 2018 |
| Second or none: Many patients treated for refractory differentiated thyroid cancer with small molecular kinase inhibitors do not receive a second line of therapy. R Copher, O Adejoro, SDC Byfield, M DuCharme, D Chatterjee, PR Joshi, ... Journal of Clinical Oncology 35 (15_suppl), e17589-e17589, 2017 | 1 | 2017 |
| P048 Herpes Zoster Incidence in Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study N Stempniewicz, A Steffens, K Kim, A Jorga, CF Bell, M DuCharme, ... Rheumatology 63 (Supplement_1), keae163. 090, 2024 | | 2024 |
| Real-World Characteristics and Ruxolitinib Treatment Patterns in 471 Patients with Chronic Graft-Versus-Host Disease in the United States J Yu, KJ Moore, N Engel-Nitz, M DuCharme, J Galvin, V Bhatt Transplantation and Cellular Therapy 30 (2), S286-S287, 2024 | | 2024 |
| POS1502 HERPES ZOSTER INCIDENCE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A RETROSPECTIVE COHORT STUDY N Stempniewicz, A Steffens, K Kim, A Jorga, C Bell, M Ducharme, H Trenz, ... Annals of the Rheumatic Diseases 82 (Suppl 1), 1108-1109, 2023 | | 2023 |
| RWD178 Real-World Treatment Patterns, Healthcare Resource Utilization (HRU) and Costs for Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL): Chimeric Antigen Receptor T … C Feng, L Murphy, N Engel-Nitz, A Nguyen, A Patel, M DuCharme, C Fu, ... Value in Health 26 (6), S395, 2023 | | 2023 |
| PRS28 Real-World Health Care Resource Utilization (HCRU) and Clinical Outcomes Among Maintenance-Naive Patients with COPD Initiating Combination Tiotropium+ Olodaterol (TIO+ … SR Palli, M DuCharme, A Anderson, M Frazer, AR Buikema, ... Value in Health 23, S721, 2020 | | 2020 |
| Costs, exacerbations and pneumonia after initiating combination tiotropium olodaterol versus triple therapy for chronic obstructive pulmonary disease (vol 8, pg 1299, 2019) SR Palli, AR Buikema, M DuCharme, M Frazer, S Kaila, T Juday JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH 9 (8), 595-597, 2020 | | 2020 |
| Evaluation of Real-World Health Care Resource Utilization (HCRU) Among Patients with COPD Initiating Combination Tiotropium/Olodaterol Versus Triple Therapy S Palli, M Frazer, M DuCharme, AR Buikema, AJ Anderson, J Elder D21. HEALTH CARE QUALITY AND UTILIZATION IN PATIENTS WITH COPD, A6274-A6274, 2020 | | 2020 |
| Evaluation of clinical outcomes within baseline exacerbation subgroups among patients with COPD initiating combination tiotropium/olodaterol versus triple therapy SR Palli, AJA MS, LL MS, MF MS D21. HEALTH CARE QUALITY AND UTILIZATION IN PATIENTS WITH COPD, A6264-A6264, 2020 | | 2020 |
| Cost burden in COPD patients initiating ICS vs. non-ICS maintenance regimens S Palli, A Buikema, M Ducharme, A Johnson, M Frazer, J Elder European Respiratory Journal 54 (suppl 63), 2019 | | 2019 |
| Healthcare Costs in Patients with Lethal Acute Graft-Versus-Host Disease (aGVHD) Post Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) in the United States J Yu, L Lal, M DuCharme, A Anderson, S Parasuraman, DJ Weisdorf Biology of Blood and Marrow Transplantation 25 (3), S244, 2019 | | 2019 |
